---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008065"
form_type: "8-K"
ticker: "TVGN"
cik: "0001860871"
company_name: "Tevogen Bio Holdings Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:27:31.910053+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tevogen Bio shareholders approve 100M share increase and reverse stock split authorization

## Summary
- Shareholders approved amending 2024 Omnibus Incentive Plan to add 100,000,000 shares, effective Feb 19, 2026.
- Shareholders authorized reverse stock split at ratio between 1:25 and 1:85, with exact ratio set by Board in its discretion.
- Both proposals passed with strong support: 147.8M for plan amendment; 176.3M for reverse split (no broker non-votes on split).
- 182.4 million shares were represented at the special meeting, ~90.5% of outstanding 201.5M shares.

## SEC filing metadata
- accession: 0001493152-26-008065
- form_type: 8-K
- ticker: TVGN
- cik: 0001860871
- company_name: Tevogen Bio Holdings Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860871/000149315226008065/0001493152-26-008065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860871/000149315226008065/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008065
- JSON: https://secwatch.observer/filing/0001493152-26-008065.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.